Six country vignettes : Strengthening radiotherapy and theranostics
Copyright © 2024. Published by Elsevier Ltd..
BACKGROUND: For cancer patient populations worldwide, the synchronous scale-up of diagnostics and treatments yields meaningful gains in survival and quality of life. Among advanced cancer therapies, radiotherapy (RT) and theranostics are key to achieving practical, high-quality, and personalized precision medicine - targeting disease manifestations of individual patients and broad populations, alike. Aiming to learn from one another across different world regions, the six country vignettes presented here depict both challenges and victories in de novo establishment or improvement of RT and theranostics infrastructure.
METHODS: The International Atomic Energy Agency (IAEA) convened global RT and theranostics experts from diverse world regions and contexts to identify relevant challenges and report progress in their own six countries: Belgium, Brazil, Costa Rica, Jordan, Mongolia, and South Africa. These accounts are collated, compared, and contrasted herein.
RESULTS: Common challenges persist which could be more strategically assessed and addressed. A quantifiable discrepancy entails personnel. The estimated radiation oncologists (ROs), nuclear medicine physicians (NMPs), and medical physicists (MPs for RT and nuclear medicine) per million inhabitants in the six collective countries respectively range between 2.69-38.00 ROs, 1.00-26.00 NMPs, and 0.30-3.45 MPs (Table 1), reflecting country-to-country inequities which largely match World Bank country-income stratifications.
CONCLUSION: Established goals for RT and nuclear medicine advancement worldwide have proven elusive. The pace of progress could be hastened by enhanced approaches such as more sustainably phased implementation; better multinational networking to share lessons learned; routine quality and safety audits; as well as capacity building employing innovative, resource-sparing, cutting-edge technologic approaches. Bodies such as ministries of health, professional societies, and the IAEA shall serve critical roles in convening and coordinating more innovative RT and theranostics translational research, including expanding nuanced global database metrics to inform, reach, and potentiate milestones most meaningfully.
POLICY SUMMARY: Aligned with WHO 25×25 NCDs target; WHA70.12 and WHA76.5 resolutions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Journal of cancer policy - 40(2024) vom: 29. März, Seite 100471 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mikhail-Lette, Miriam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Brachytherapy |
|---|
| Anmerkungen: |
Date Revised 11.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.jcpo.2024.100471 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370456483 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370456483 | ||
| 003 | DE-627 | ||
| 005 | 20240412233210.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240401s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcpo.2024.100471 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1373.xml |
| 035 | |a (DE-627)NLM370456483 | ||
| 035 | |a (NLM)38556128 | ||
| 035 | |a (PII)S2213-5383(24)00005-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mikhail-Lette, Miriam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Six country vignettes |b Strengthening radiotherapy and theranostics |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024. Published by Elsevier Ltd. | ||
| 520 | |a BACKGROUND: For cancer patient populations worldwide, the synchronous scale-up of diagnostics and treatments yields meaningful gains in survival and quality of life. Among advanced cancer therapies, radiotherapy (RT) and theranostics are key to achieving practical, high-quality, and personalized precision medicine - targeting disease manifestations of individual patients and broad populations, alike. Aiming to learn from one another across different world regions, the six country vignettes presented here depict both challenges and victories in de novo establishment or improvement of RT and theranostics infrastructure | ||
| 520 | |a METHODS: The International Atomic Energy Agency (IAEA) convened global RT and theranostics experts from diverse world regions and contexts to identify relevant challenges and report progress in their own six countries: Belgium, Brazil, Costa Rica, Jordan, Mongolia, and South Africa. These accounts are collated, compared, and contrasted herein | ||
| 520 | |a RESULTS: Common challenges persist which could be more strategically assessed and addressed. A quantifiable discrepancy entails personnel. The estimated radiation oncologists (ROs), nuclear medicine physicians (NMPs), and medical physicists (MPs for RT and nuclear medicine) per million inhabitants in the six collective countries respectively range between 2.69-38.00 ROs, 1.00-26.00 NMPs, and 0.30-3.45 MPs (Table 1), reflecting country-to-country inequities which largely match World Bank country-income stratifications | ||
| 520 | |a CONCLUSION: Established goals for RT and nuclear medicine advancement worldwide have proven elusive. The pace of progress could be hastened by enhanced approaches such as more sustainably phased implementation; better multinational networking to share lessons learned; routine quality and safety audits; as well as capacity building employing innovative, resource-sparing, cutting-edge technologic approaches. Bodies such as ministries of health, professional societies, and the IAEA shall serve critical roles in convening and coordinating more innovative RT and theranostics translational research, including expanding nuanced global database metrics to inform, reach, and potentiate milestones most meaningfully | ||
| 520 | |a POLICY SUMMARY: Aligned with WHO 25×25 NCDs target; WHA70.12 and WHA76.5 resolutions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Brachytherapy | |
| 650 | 4 | |a Global health | |
| 650 | 4 | |a Low-middle-income countries | |
| 650 | 4 | |a Nuclear medicine | |
| 650 | 4 | |a Public health | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 4 | |a Theranostics | |
| 700 | 1 | |a Cordero, Lisbeth |e verfasserin |4 aut | |
| 700 | 1 | |a Lievens, Yolande |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Ibraheem, Akram |e verfasserin |4 aut | |
| 700 | 1 | |a Urbain, Jean-Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Chera, Bhishamjit |e verfasserin |4 aut | |
| 700 | 1 | |a Muylle, Kristoff |e verfasserin |4 aut | |
| 700 | 1 | |a Vaandering, Aude |e verfasserin |4 aut | |
| 700 | 1 | |a Rosa, Arthur Accioly |e verfasserin |4 aut | |
| 700 | 1 | |a Cerci, Juliano Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Sathekge, Mike |e verfasserin |4 aut | |
| 700 | 1 | |a Minjgee, Minjmaa |e verfasserin |4 aut | |
| 700 | 1 | |a Nansalmaa, Erdenekhuu |e verfasserin |4 aut | |
| 700 | 1 | |a Erdenechimeg, Sereegotov |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz, Rolando Loría |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Paez, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Giammarile, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Veduta, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Minoshima, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Vichare, Shrikant |e verfasserin |4 aut | |
| 700 | 1 | |a Abdel-Wahab, May |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cancer policy |d 2014 |g 40(2024) vom: 29. März, Seite 100471 |w (DE-627)NLM241976499 |x 2213-5383 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2024 |g day:29 |g month:03 |g pages:100471 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcpo.2024.100471 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2024 |b 29 |c 03 |h 100471 | ||